# A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

> **NCT05692154** · PHASE3 · COMPLETED · sponsor: **Opella Healthcare Group SAS, a Sanofi Company** · enrollment: 95 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Fexofenadine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05692154
- **Lead sponsor:** Opella Healthcare Group SAS, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-23
- **Primary completion:** 2023-03-14
- **Final completion:** 2023-03-14
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05692154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05692154, "A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05692154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*